These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27634566)

  • 1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
    Sweis RF; Medved M; Towey S; Karczmar GS; Oto A; Szmulewitz RZ; O'Donnell PH; Fishkin P; Karrison T; Stadler WM
    Clin Genitourin Cancer; 2017 Apr; 15(2):207-212. PubMed ID: 27634566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
    Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
    Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
    Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
    Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
    J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
    Verbiest A; Couchy G; Job S; Zucman-Rossi J; Caruana L; Lerut E; Oyen R; de Reyniès A; Laguerre B; Rioux-Leclercq N; Wozniak A; Joniau S; Van Poppel H; Van Den Eynde K; Beuselinck B
    Clin Genitourin Cancer; 2018 Jun; 16(3):e605-e612. PubMed ID: 29239846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
    J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
    Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
    Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
    Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
    Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
    Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
    J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
    J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy.
    Xu L; Ge X; Sun N; Liu X
    Acta Radiol; 2020 Oct; 61(10):1316-1325. PubMed ID: 32053003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.